Past, present, and future of Parkinson's disease: A speci of the Shaking Palsy

Movement Disorders

32, 1264-1310

DOI: 10.1002/mds.27115

Citation Report

#	Article	IF	Citations
1	Past, present, and future of Parkinson's disease. Movement Disorders, 2017, 32, 1263-1263.	2.2	4
3	Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinsonâ€™s Disease. Frontiers in Genetics, 2017, 8, 177.	1.1	58
4	Insights into Parkinsonâ€™s disease from computational models of the basal ganglia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1181-1188.	0.9	54
5	Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinsonâ€™s Disease Patients? A Systematic Review. Journal of Parkinson's Disease, 2018, 8, 217-231.	1.5	15
6	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Movement Disorders, 2018, 33, 660-677.	2.2	275
7	Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 33-43.	1.5	41
8	Parkinson disease and the risk of epileptic seizures. Annals of Neurology, 2018, 83, 363-374.	2.8	54
9	Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease. Journal of Neurochemistry, 2018, 144, 691-709.	2.1	58
10	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. Movement Disorders, 2018, 33, 501-502.	2.2	1
11	Autonomic dysfunction in Parkinson's disease and other synucleinopathies: Introduction to the series. Movement Disorders, 2018, 33, 347-348.	2.2	9
12	Immunologic treatment of Parkinson's disease. Immunotherapy, 2018, 10, 81-84.	1.0	16
13	The genetics of Parkinson disease. Ageing Research Reviews, 2018, 42, 72-85.	5.0	398
14	Changing views after 200 years of Parkinson disease. Nature Reviews Neurology, 2018, 14, 70-72.	4.9	11
15	Recent Trends in the Use of Electrical Neuromodulation in Parkinsonâ€™s Disease. Current Behavioral Neuroscience Reports, 2018, 5, 170-178.	0.6	20
16	Prenatal exposure to oxidative phosphorylation xenobiotics and late-onset Parkinson disease. Ageing Research Reviews, 2018, 45, 24-32.	5.0	10
17	Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques. Journal of Neuroscience Methods, 2018, 303, 30-40.	1.3	10
18	Sudden Unexpected Death in Parkinsonâ€™s Disease (SUDPAR): a fatal event that James Parkinson did not address. Age and Ageing, 2018, 47, 627-627.	0.7	2
19	Membranes as modulators of amyloid protein misfolding and target of toxicity. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1863-1875.	1.4	34

#	Article	IF	Citations
20	Parkinsonâ€™s disease: experimental models and reality. Acta Neuropathologica, 2018, 135, 13-32.	3.9	89
21	Resveratrol provides neuroprotective effects through modulation of mitochondrial dynamics and ERK1/2 regulated autophagy. Free Radical Research, 2018, 52, 1371-1386.	1.5	53
22	Gene therapy reduces Parkinsonâ€™s disease symptoms by reorganizing functional brain connectivity. Science Translational Medicine, 2018, 10, .	5.8	58
23	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nature Reviews Drug Discovery, 2018, 17, 804-822.	21.5	178
24	Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats. Neurochemical Research, 2018, 43, 2132-2140.	1.6	30
25	Osteocalcin Ameliorates Motor Dysfunction in a 6-Hydroxydopamine-Induced Parkinsonâ€™s Disease Rat Model Through AKT/GSK3Î² Signaling. Frontiers in Molecular Neuroscience, 2018, 11, 343.	1.4	24
26	Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease. Neurology: Genetics, 2018, 4, e271.	0.9	12
27	A Cortical Pathogenic Theory of Parkinsonâ€™s Disease. Neuron, 2018, 99, 1116-1128.	3.8	108
28	Proteasome-targeted nanobodies alleviate pathology and functional decline in an Î±-synuclein-based Parkinsonâ€™s disease model. Npj Parkinson's Disease, 2018, 4, 25.	2.5	61
29	Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brainâ€derived neurotrophic factor. Journal of Neurochemistry, 2018, 147, 678-691.	2.1	17
30	Adenosine Receptors and Neuroinflammation. , 2018, , 217-237.		2
31	Parkinsonâ€™s disease: what the model systems have taught us so far. Journal of Genetics, 2018, 97, 729-751.	0.4	15
32	Microglia Polarization, Gene-Environment Interactions and Wnt/Î²-Catenin Signaling: Emerging Roles of Glia-Neuron and Glia-Stem/Neuroprogenitor Crosstalk for Dopaminergic Neurorestoration in Aged Parkinsonian Brain. Frontiers in Aging Neuroscience, 2018, 10, 12.	1.7	71
33	Diagnostic Criteria for Parkinsonâ€™s Disease: From James Parkinson to the Concept of Prodromal Disease. Frontiers in Neurology, 2018, 9, 156.	1.1	136
34	Informed Consent Decision-Making in Deep Brain Stimulation. Brain Sciences, 2018, 8, 84.	1.1	7
36	The role of T cells in the pathogenesis of Parkinsonâ€™s disease. Progress in Neurobiology, 2018, 169, 1-23.	2.8	64
37	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2018, 17, 597-608.	4.9	101
38	Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. Neurobiology of Disease, 2018, 118, 1-8.	2.1	22

#	Article	IF	Citations
39	The enteric nervous system in PD: gateway, bystander victim, or source of solutions. Cell and Tissue Research, 2018, 373, 313-326.	1.5	19
40	Treatment options for postural instability and gait difficulties in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2019, 19, 1229-1251.	1.4	22
41	Exploring the Mitochondrial Degradome by the TAILS Proteomics Approach in a Cellular Model of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 195.	1.7	7
42	Focused ultrasound in Parkinson's disease: A twofold path toward disease modification. Movement Disorders, 2019, 34, 1262-1273.	2.2	25
43	Bioenergetics and translational metabolism: implications for genetics, physiology and precision medicine. Biological Chemistry, 2019, 401, 3-29.	1.2	41
44	Motor function and the probability of prodromal Parkinson's disease in older adults. Movement Disorders, 2019, 34, 1345-1353.	2.2	16
45	Endogenous protection against the 6-OHDA model of Parkinson's disease in the Amazonian rodent Proechimys. Neuroscience Letters, 2019, 709, 134381.	1.0	3
46	Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial. Neurobiology of Disease, 2019, 130, 104530.	2.1	11
47	Dermatoses in parkinsonism: the importance of multidisciplinary follow-up. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2019, 65, 791-795.	0.3	5
48	Pragmatism and the Importance of Interdisciplinary Teams in Investigating Personality Changes Following DBS. Neuroethics, 2021, 14, 95-105.	1.7	22
49	Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinsonâ€™s disease. Nature Communications, 2019, 10, 5094.	5.8	65
50	Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 83-121.	1.0	12
51	Prevalence of self-reported movement dysfunction among young adults with a history of ecstasy and methamphetamine use. Drug and Alcohol Dependence, 2019, 205, 107595.	1.6	4
52	Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinsonâ€™s disease patients. Journal of Clinical Neuroscience, 2019, 70, 198-201.	0.8	17
53	Animal Models for Parkinsonâ€™s Disease Research: Trends in the 2000s. International Journal of Molecular Sciences, 2019, 20, 5402.	1.8	86
54	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. Movement Disorders, 2019, 34, 1406-1422.	2.2	62
55	Quantitative Susceptibility Mapping and Resting State Network Analyses in Parkinsonian Phenotypesâ€”A Systematic Review of the Literature. Frontiers in Neural Circuits, 2019, 13, 50.	1.4	5
56	Sudden unexpected death in Parkinsonâ€™s disease: why is drinking water important?. Neurodegenerative Disease Management, 2019, 9, 241-246.	1.2	7

#	Article	IF	Citations
57	Immunotherapy in Parkinsonâ€™s disease: Current status and future directions. Neurobiology of Disease, 2019, 132, 104587.	2.1	41
58	Bioenergetics and Autophagic Imbalance in Patients-Derived Cell Models of Parkinson Disease Supports Systemic Dysfunction in Neurodegeneration. Frontiers in Neuroscience, 2019, 13, 894.	1.4	29
59	Cerebral differences between dopamine-resistant and dopamine-responsive Parkinsonâ€™s tremor. Brain, 2019, 142, 3144-3157.	3.7	54
60	Postural Instability in Parkinsonâ€™s Disease: A Review. Brain Sciences, 2019, 9, 239.	1.1	64
61	Pilot Study of the International Parkinson and Movement Disorder Societyâ€sponsored Nonâ€motor Rating Scale (MDSâ€NMS). Movement Disorders Clinical Practice, 2019, 6, 227-234.	0.8	31
62	Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinsonâ€™s Disease. Cells, 2019, 8, 105.	1.8	30
63	Editor's note: The origin of Parkinson's disease: The importance of environment and lifestyle. Movement Disorders, 2019, 34, 799-800.	2.2	0
64	Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical updateâ€”I. Hypokinetic-rigid movement disorders. Journal of Neural Transmission, 2019, 126, 933-995.	1.4	28
65	Extracellular Î±â€synuclein enters dopaminergic cells by modulating flotillinâ€1â€“assisted dopamine transporter endocytosis. FASEB Journal, 2019, 33, 10240-10256.	0.2	16
66	Cognitive and behavioral assessment in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2019, 19, 613-622.	1.4	7
67	Gait stride-to-stride variability and foot clearance pattern analysis in Idiopathic Parkinsonâ€™s Disease and Vascular Parkinsonism. Journal of Biomechanics, 2019, 92, 98-104.	0.9	16
68	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism and Related Disorders, 2019, 65, 39-48.	1.1	69
69	Combined Assessment of Diffusion Parameters and Cerebral Blood Flow Within Basal Ganglia in Early Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 134.	1.7	21
70	Enhancing the Astrocytic Clearance of Extracellular Î±-Synuclein Aggregates by Ginkgolides Attenuates Neural Cell Injury. Cellular and Molecular Neurobiology, 2019, 39, 1017-1028.	1.7	24
71	Comparison of Actions between L-DOPA and Different Dopamine Agonists in Striatal DA-Depleted Microcircuits In Vitro: Pre-Clinical Insights. Neuroscience, 2019, 410, 76-96.	1.1	11
72	Neurodegeneration and contralateral Î±-synuclein induction after intracerebral Î±-synuclein injections in the anterior olfactory nucleus of a Parkinsonâ€™s disease A53T mouse model. Acta Neuropathologica Communications, 2019, 7, 56.	2.4	13
73	Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies. Neurology, 2019, 92, e1821-e1830.	1.5	88
74	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. American Journal of Geriatric Psychiatry, 2019, 27, 998-1018.	0.6	82

#	Article	IF	Citations
75	Motor Improvement-Related Regional Cerebral Blood Flow Changes in Parkinsonâ€™s Disease in Response to Antiparkinsonian Drugs. Parkinson's Disease, 2019, 2019, 1-8.	0.6	4
76	Extended-Release Amantadine for Levodopa-Induced Dyskinesia. Expert Review of Neurotherapeutics, 2019, 19, 293-299.	1.4	8
77	Prodromal Parkinson's Disease: The Decade Past, the Decade to Come. Movement Disorders, 2019, 34, 665-675.	2.2	120
78	Mild cognitive impairment in Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 897-904.	1.4	33
79	Targeting Î±-Synuclein in Parkinsonâ€™s Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Drugs, 2019, 79, 797-810.	4.9	67
80	Biomarkers of Parkinsonâ€™s disease: 20Âyears later. Journal of Neural Transmission, 2019, 126, 803-813.	1.4	22
81	Concordance for Parkinson's disease in twins: A 20â€year update. Annals of Neurology, 2019, 85, 600-605.	2.8	64
82	Compulsive eating behaviors in Parkinsonâ€™s disease. Eating and Weight Disorders, 2019, 24, 421-429.	1.2	12
83	NIR Biosensing of Neurotransmitters in Stem Cellâ€Derived Neural Interface Using Advanced Coreâ€“Shell Upconversion Nanoparticles. Advanced Materials, 2019, 31, e1806991.	11.1	97
84	Diabetes, a Contemporary Risk for Parkinsonâ€™s Disease: Epidemiological and Cellular Evidences. Frontiers in Aging Neuroscience, 2019, 11, 302.	1.7	53
85	Uridine Prevents Negative Effects of OXPHOS Xenobiotics on Dopaminergic Neuronal Differentiation. Cells, 2019, 8, 1407.	1.8	4
86	Enfermedad de Parkinson y parkinsonismos. Medicine, 2019, 12, 4273-4284.	0.0	1
87	DJ-1 regulates the integrity and function of ER-mitochondria association through interaction with IP3R3-Grp75-VDAC1. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25322-25328.	3.3	156
88	Diet in Parkinson's Disease: Critical Role for the Microbiome. Frontiers in Neurology, 2019, 10, 1245.	1.1	83
89	The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife. Frontiers in Neurology, 2019, 10, 1328.	1.1	16
90	NCS-1 Deficiency Affects mRNA Levels of Genes Involved in Regulation of ATP Synthesis and Mitochondrial Stress in Highly Vulnerable Substantia nigra Dopaminergic Neurons. Frontiers in Molecular Neuroscience, 2019, 12, 252.	1.4	13
91	Targeting Alpha-Synuclein as a Therapy for Parkinsonâ€™s Disease. Frontiers in Molecular Neuroscience, 2019, 12, 299.	1.4	215
92	EEG coherence as a diagnostic tool to measure the initial stages of Parkinson Disease. Medical Hypotheses, 2019, 123, 74-78.	0.8	9

#	Article	IF	Citations
93	Parkinsonâ€™s Disease in the Era of Personalised Medicine: One Size Does Not Fit All. Drugs and Aging, 2019, 36, 103-113.	1.3	27
94	The next chapter in symptomatic Parkinson disease treatments. Parkinsonism and Related Disorders, 2019, 59, 39-48.	1.1	2
95	Pathogenesisâ€targeted therapeutic strategies in Parkinson's disease. Movement Disorders, 2019, 34, 41-44.	2.2	44
96	5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 212-215.	1.0	11
97	Exogenous Tetranectin Protects Against 1-Methyl-4-Phenylpyridineâ€“Induced Neurotoxicity by Inhibiting Apoptosis and Autophagy Through Ribosomal Protein S6 Kinase Beta-1. World Neurosurgery, 2019, 122, e375-e382.	0.7	6
98	Parkinson's disease: Evolution of the scientific literature from 1983 to 2017 by countries and journals. Parkinsonism and Related Disorders, 2019, 61, 10-18.	1.1	17
99	The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease. Annual Review of Pharmacology and Toxicology, 2019, 59, 263-289.	4.2	80
100	Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Molecular Neurobiology, 2019, 56, 4799-4811.	1.9	28
101	Parkinsonâ€™s Disease. Medical Clinics of North America, 2019, 103, 337-350.	1.1	269
102	The PPARGC1A locus and CNS-specific PGC-1Î± isoforms are associated with Parkinson's Disease. Neurobiology of Disease, 2019, 121, 34-46.	2.1	23
103	Deregulation of autophagy and vesicle trafficking in Parkinsonâ€™s disease. Neuroscience Letters, 2019, 697, 59-65.	1.0	36
104	Transplantation of Nurr1â€overexpressing neural stem cells and microglia for treating parkinsonian rats. CNS Neuroscience and Therapeutics, 2020, 26, 55-65.	1.9	14
105	Effect of Repetitive Transcranial Magnetic Stimulation on Gait and Freezing of Gait in Parkinson Disease: A Systematic Review and Meta-analysis. Archives of Physical Medicine and Rehabilitation, 2020, 101, 130-140.	0.5	19
106	SINEUP Non-coding RNA Targeting GDNF Rescues Motor Deficits and Neurodegeneration in a Mouse Model of Parkinsonâ€™s Disease. Molecular Therapy, 2020, 28, 642-652.	3.7	41
107	Are genetic and idiopathic forms of Parkinson's disease the same disease?. Journal of Neurochemistry, 2020, 152, 515-522.	2.1	28
108	Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinsonâ€™s Disease and l-DOPA-Induced Dyskinesia. Neurotoxicity Research, 2020, 37, 12-29.	1.3	33
109	Stress-related vulnerability and usefulness of healthcare education in Parkinson's disease: The perception of a group of family caregivers, a cross-sectional study. Applied Nursing Research, 2020, 51, 151186.	1.0	5
110	Non-toxic HSC Transplantation-Based Macrophage/Microglia-Mediated GDNF Delivery for Parkinsonâ€™s Disease. Molecular Therapy - Methods and Clinical Development, 2020, 17, 83-98.	1.8	16

#	Article	IF	Citations
111	Metabolic Network Abnormalities in Drugâ€NaÃ¯ve Parkinson's Disease. Movement Disorders, 2020, 35, 587-594.	2.2	19
112	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. Clinics in Geriatric Medicine, 2020, 36, 105-118.	1.0	18
113	Impaired Motor Control and Neurologic Rehabilitation in Older Adults. , 2020, , 379-399.		0
114	Evolving concepts on bradykinesia. Brain, 2020, 143, 727-750.	3.7	120
115	Innate and adaptive immune responses in Parkinson's disease. Progress in Brain Research, 2020, 252, 169-216.	0.9	64
116	Synthesis and evaluation of methoxy substituted 2-benzoyl-1-benzofuran derivatives as lead compounds for the development adenosine A1 and/or A2A receptor antagonists. Bioorganic Chemistry, 2020, 94, 103459.	2.0	6
117	CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinsonâ€™s disease. Nature Communications, 2020, 11, 4885.	5.8	39
118	Co-administration of TiO2-nanowired dl-3-n-butylphthalide (dl-NBP) and mesenchymal stem cells enhanced neuroprotection in Parkinson's disease exacerbated by concussive head injury. Progress in Brain Research, 2020, 258, 101-155.	0.9	16
119	Parkinsonâ€™s disease and translational research. Translational Neurodegeneration, 2020, 9, 43.	3.6	13
120	Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO2 nanowired mesenchymal stem cells and cerebrolysin. Progress in Brain Research, 2020, 258, 157-231.	0.9	21
121	Repetitive transcranial magnetic stimulation (rTMS) fails to improve cognition in patients with parkinsonâ€™s disease: a Meta-analysis of randomized controlled trials. International Journal of Neuroscience, 2022, 132, 269-282.	0.8	7
122	Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinsonâ€™s Disease. Cells, 2020, 9, 2580.	1.8	16
123	DiagnÃ³stico y abordaje de las alteraciones asociadas a la enfermedad de Parkinson en atenciÃ³n primaria. FMC Formacion Medica Continuada En Atencion Primaria, 2020, 27, 293-299.	0.0	0
124	Animal Models of Parkinsonâ€™s Disease: Are They Useful or Not?. Journal of Parkinson's Disease, 2020, 10, 1335-1342.	1.5	22
125	Impact of circadian and diurnal rhythms on cellular metabolic function and neurodegenerative diseases. International Review of Neurobiology, 2020, 154, 393-412.	0.9	5
126	Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia. Frontiers in Aging Neuroscience, 2020, 12, 230.	1.7	18
127	Lower Urinary Tract and Gastrointestinal Dysfunction Are Common in Early Parkinsonâ€™s Disease. Parkinson's Disease, 2020, 2020, 1-8.	0.6	4
128	Novel Drosophila model for parkinsonism by targeting phosphoglycerate kinase. Neurochemistry International, 2020, 139, 104816.	1.9	7

#	Article	IF	Citations
129	Baroreflex function in Parkinson's disease: insights from the modified-Oxford technique. Journal of Neurophysiology, 2020, 124, 1144-1151.	0.9	9
130	Post-GWAS knowledge gap: the how, where, and when. Npj Parkinson's Disease, 2020, 6, 23.	2.5	19
131	Extracellular Vesicles as Nanotherapeutics for Parkinsonâ€™s Disease. Biomolecules, 2020, 10, 1327.	1.8	19
132	Calcium, Bioenergetics, and Parkinsonâ€™s Disease. Cells, 2020, 9, 2045.	1.8	46
133	The cis-Regulatory Element of SNCA Intron 4 Modulates Susceptibility to Parkinsonâ€™s Disease in Han Chinese. Frontiers in Genetics, 2020, 11, 590365.	1.1	0
134	Altered baseline and amphetamine-mediated behavioral profiles in dopamine transporter Cre (DAT-Ires-Cre) mice compared to tyrosine hydroxylase Cre (TH-Cre) mice. Psychopharmacology, 2020, 237, 3553-3568.	1.5	16
135	Can We Put Aside Microelectrode Recordings in Deep Brain Stimulation Surgery?. Brain Sciences, 2020, 10, 571.	1.1	11
136	Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2020, 12, 232.	1.7	1
137	Bu-Yin-Qian-Zheng Formula Ameliorates MPP+-Induced Mitochondrial Dysfunction in Parkinsonâ€™s Disease via Parkin. Frontiers in Pharmacology, 2020, 11, 577017.	1.6	3
138	Quality of Life in Newly Diagnosed Patients With Parkin-Related Parkinson's Disease. Frontiers in Neurology, 2020, 11, 580910.	1.1	6
139	In vivo patch-clamp recordings reveal distinct subthreshold signatures and threshold dynamics of midbrain dopamine neurons. Nature Communications, 2020, 11, 6286.	5.8	26
140	Mitochondrial Dysfunction in Parkinsonâ€™s Disease: Focus on Mitochondrial DNA. Biomedicines, 2020, 8, 591.	1.4	30
141	Ractopamine residue in meat might protect people from Parkinson disease. Medical Hypotheses, 2020, 145, 110397.	0.8	4
142	Energy Metabolism Decline in the Aging Brainâ€”Pathogenesis of Neurodegenerative Disorders. Metabolites, 2020, 10, 450.	1.3	55
143	Psychiatric Discourse: Scientific Reductionism for the Autonomous Person. , 2020, , 495-509.		0
144	Macular Abnormalities Associated With 5Î±-Reductase Inhibitor. JAMA Ophthalmology, 2020, 138, 732.	1.4	8
145	Clinical and Imaging Markers of Prodromal Parkinson's Disease. Frontiers in Neurology, 2020, 11, 395.	1.1	88
146	Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms. Nature Communications, 2020, 11, 2388.	5.8	37

#	Article	IF	Citations
147	When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis. Journal of Neurology, 2021, 268, 3203-3211.	1.8	16
148	A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease. Movement Disorders, 2020, 35, 1802-1809.	2.2	15
149	Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 118.	1.7	17
150	The human olfactory system in two proteinopathies: Alzheimerâ€™s and Parkinsonâ€™s diseases. Translational Neurodegeneration, 2020, 9, 22.	3.6	62
151	Management of psychiatric disorders in Parkinson's disease. Neurotherapeutics, 2020, 17, 1511-1524.	2.1	19
152	The gut microbiome in Parkinson's disease: A culprit or a bystander?. Progress in Brain Research, 2020, 252, 357-450.	0.9	70
153	PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2020, 15, 20.	4.4	264
154	Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 613-621.	1.5	3
155	Glia-Derived Extracellular Vesicles in Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 1941.	1.0	18
156	Development of early diagnosis of Parkinson's disease: Illusion or reality?. CNS Neuroscience and Therapeutics, 2020, 26, 997-1009.	1.9	45
157	Parkinson's disease a futile entangle of Mankind's credence on an herbal remedy: A review. Life Sciences, 2020, 257, 118019.	2.0	0
158	Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17296-17307.	3.3	47
159	Parkinsonâ€™s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 795-808.	0.9	459
160	Small-molecule inhibitors of Î±-synuclein for the treatment of Parkinsonâ€™s disease: a patent landscape. Pharmaceutical Patent Analyst, 2020, 9, 63-65.	0.4	1
161	Gut, oral and nasal microbiota and Parkinsonâ€™s disease. Microbial Cell Factories, 2020, 19, 50.	1.9	38
162	Network degeneration in Parkinsonâ€™s disease: multimodal imaging of nigro-striato-cortical dysfunction. Brain, 2020, 143, 944-959.	3.7	74
163	Forkhead Box O3a requires BAF57, a subunit of chromatin remodeler SWI/SNF complex for induction of p53 upâ€regulated modulator of apoptosisÂ(Puma) in a model of Parkinsonâ€™s disease. Journal of Neurochemistry, 2020, 154, 547-561.	2.1	20
164	Mitochondrial Dysfunction Combined with High Calcium Load Leads to Impaired Antioxidant Defense Underlying the Selective Loss of Nigral Dopaminergic Neurons. Journal of Neuroscience, 2020, 40, 1975-1986.	1.7	34

#	Article	IF	Citations
165	APOE genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine, 2020, 12, .	5.8	102
166	Parkinson disease and the immune system â€" associations, mechanisms and therapeutics. Nature Reviews Neurology, 2020, 16, 303-318.	4.9	254
167	Boosting Antioxidant Self-defenses by Grafting Astrocytes Rejuvenates the Aged Microenvironment and Mitigates Nigrostriatal Toxicity in Parkinsonian Brain via an Nrf2-Driven Wnt/Î²-Catenin Prosurvival Axis. Frontiers in Aging Neuroscience, 2020, 12, 24.	1.7	23
168	From cell lines to pluripotent stem cells for modelling Parkinson's Disease. Journal of Neuroscience Methods, 2020, 340, 108741.	1.3	26
169	Î±-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Molecular Neurodegeneration, 2020, 15, 27.	4.4	35
170	The Role of VPS35 in the Pathobiology of Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2021, 41, 199-227.	1.7	35
171	Update on the association between alphaâ€synuclein and tau with mitochondrial dysfunction: Implications for Parkinson's disease. European Journal of Neuroscience, 2021, 53, 2946-2959.	1.2	24
172	In vitro neuroprotective potential of Clivia miniata and Nerine humilis (Amaryllidaceae) in MPP+-induced neuronal toxicity in SH-SY5Y neuroblastoma cells. South African Journal of Botany, 2021, 136, 110-117.	1.2	12
174	Motor asymmetry related cerebral perfusion patterns in Parkinson's disease: An arterial spin labeling study. Human Brain Mapping, 2021, 42, 298-309.	1.9	20
175	Modeling the pathophysiology of Parkinsonâ€™s disease in patient-specific neurons. Experimental Biology and Medicine, 2021, 246, 298-304.	1.1	0
176	Mitochondria and Parkinsonâ€™s Disease: Clinical, Molecular, and Translational Aspects. Journal of Parkinson's Disease, 2021, 11, 45-60.	1.5	100
177	Mutation analysis of LRP10 in a large Chinese familial Parkinson disease cohort. Neurobiology of Aging, 2021, 99, 99.e1-99.e6.	1.5	6
178	Therapeutic Path to Double Knockout: Investigating the Selective Dual-Inhibitory Mechanisms of Adenosine Receptors A1 and A2 by a Novel Methoxy-Substituted Benzofuran Derivative in the Treatment of Parkinsonâ€™s Disease. Cell Biochemistry and Biophysics, 2021, 79, 25-36.	0.9	3
179	Stretchable triboelectric sensor for measurement of the forearm muscles movements and fingers motion for Parkinson's disease assessment and assisting technologies. Medical Devices & Sensors, 2021, 4, e10154.	2.7	16
180	Mutation analysis of TMEM family members for early-onset Parkinsonâ€™s disease in Chinese population. Neurobiology of Aging, 2021, 101, 299.e1-299.e6.	1.5	14
181	LRRK2 at the preâ€synaptic site: A 16â€years perspective. Journal of Neurochemistry, 2021, 157, 297-311.	2.1	17
182	Melatonin and regulation of autophagy: Mechanisms and therapeutic implications. Pharmacological Research, 2021, 163, 105279.	3.1	17
183	LRP10 Mutations May Correlate with Sporadic Parkinsonâ€™s Disease in China. Molecular Neurobiology, 2021, 58, 1212-1216.	1.9	7

#	Article	IF	Citations
184	Inflammatory lncRNA AK039862 regulates paraquat-inhibited proliferation and migration of microglial and neuronal cells through the Pafah1b1/Foxa1 pathway in co-culture environments. Ecotoxicology and Environmental Safety, 2021, 208, 111424.	2.9	9
185	Leveraging sequenceâ€based faecal microbial community survey data to identify alterations in gut microbiota among patients with Parkinson's disease. European Journal of Neuroscience, 2021, 53, 687-696.	1.2	6
186	Impact of Footwear and Foot Deformities in patients with Parkinson's disease: A Case-Series Study. International Journal of Medical Sciences, 2021, 18, 372-377.	1.1	2
187	Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders. , 2021, , 249-295.e17.		0
188	Etiology and pathogenesis of Parkinson disease. , 2021, , 121-163.e16.		2
189	Efficacy of Traditional Chinese Medicine Combined with Selective Serotonin Reuptake Inhibitors on the Treatment for Parkinsonâ€™s Disease with Depression: A Systematic Review and Meta-Analysis. The American Journal of Chinese Medicine, 2021, 49, 627-643.	1.5	19
190	Can plasma cholinesterase act as an adjuvant prognostic index in acute burn cases?. Ain Shams Journal of Forensic Medicine and Clinical Toxicology, 2021, 36, 49-60.	0.2	1
191	Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine. Progress in Brain Research, 2021, 261, 265-285.	0.9	3
192	Brain Motor Network Changes in Parkinson's Disease: Evidence from Metaâ€Analytic Modeling. Movement Disorders, 2021, 36, 1180-1190.	2.2	26
193	Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinsonâ€™s Disease. , 2021, 12, 1494.		21
194	Functional neuroanatomy of the basal ganglia. , 2021, , 70-81.e3.		0
195	Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinsonâ€™s disease. Microbiome, 2021, 9, 34.	4.9	97
196	An Update on Medical and Surgical Treatments of Parkinsonâ€™s Disease. , 2021, 12, 1021.		25
197	Motor control. , 2021, , 52-69.e5.		0
198	Role of Microgliosis and NLRP3 Inflammasome in Parkinsonâ€™s Disease Pathogenesis and Therapy. Cellular and Molecular Neurobiology, 2022, 42, 1283-1300.	1.7	31
199	Monitoring the neurotransmitter release of human midbrain organoids using a redox cycling microsensor as a novel tool for personalized Parkinson's disease modelling and drug screening. Analyst, The, 2021, 146, 2358-2367.	1.7	22
200	Neuroinflammation in Parkinsonâ€™s Disease: Triggers, Mechanisms, and Immunotherapies. Neuroscientist, 2022, 28, 364-381.	2.6	21
201	Voltage-Gated Ca2+ Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease?. Frontiers in Synaptic Neuroscience, 2021, 13, 636103.	1.3	22

#	Article	IF	Citations
202	microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers. Sleep Medicine, 2021, 78, 160-168.	0.8	6
203	Gene expression barcode values reveal a potential link between Parkinsonâ€™s disease and gastric cancer. Aging, 2021, 13, 6171-6181.	1.4	1
204	Multi-Electrode Array Analysis Identifies Complex Dopamine Responses and Glucose Sensing Properties of Substantia Nigra Neurons in Mouse Brain Slices. Frontiers in Synaptic Neuroscience, 2021, 13, 635050.	1.3	13
205	Effect of Care Rehabilitation on Medical Expenses, Care Costs, and Total Costs of Elderly Individuals with Parkinson's Disease. Population Health Management, 2021, 24, 738-747.	0.8	0
206	Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease. Neuropharmacology, 2021, 186, 108465.	2.0	10
207	The Impact of Depression Symptoms in Patients with Parkinsonâ€™s Disease: A Novel Case-Control Investigation. International Journal of Environmental Research and Public Health, 2021, 18, 2369.	1.2	11
208	Rheumatoid arthritis decreases risk for Parkinsonâ€™s disease: a Mendelian randomization study. Npj Parkinson's Disease, 2021, 7, 17.	2.5	28
209	Current State-of-the-Art and Unresolved Problems in Using Human Induced Pluripotent Stem Cell-Derived Dopamine Neurons for Parkinsonâ€™s Disease Drug Development. International Journal of Molecular Sciences, 2021, 22, 3381.	1.8	11
210	Enfermedad de Parkinson: actualizaciÃ³n de estudios preclÃnicos con el uso de cÃ©lulas troncales pluripotentes inducidas. NeurologÃa, 2021, , .	0.3	1
211	Sinapic Acid Protects SH-SY5Y Human Neuroblastoma Cells against 6-Hydroxydopamine-Induced Neurotoxicity. Biomedicines, 2021, 9, 295.	1.4	12
212	Active lifestyle enhances protein expression profile in subjects with Lewy body pathology. Dementia E Neuropsychologia, 2021, 15, 41-50.	0.3	4
213	Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 2737.	1.8	44
215	Cell-penetrating, antioxidant SELENOT mimetic protects dopaminergic neurons and ameliorates motor dysfunction in Parkinson's disease animal models. Redox Biology, 2021, 40, 101839.	3.9	20
216	The role of gut dysbiosis in Parkinsonâ€™s disease: mechanistic insights and therapeutic options. Brain, 2021, 144, 2571-2593.	3.7	119
217	Synucleinopathy-associated pathogenesis in Parkinsonâ€™s disease and the potential for brain-derived neurotrophic factor. Npj Parkinson's Disease, 2021, 7, 35.	2.5	26
218	Baroreflex dysfunction in Parkinsonâ€™s disease: integration of central and peripheral mechanisms. Journal of Neurophysiology, 2021, 125, 1425-1439.	0.9	12
219	A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity. International Journal of Molecular Sciences, 2021, 22, 4341.	1.8	2
220	LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation. Brain, 2021, 144, 1509-1525.	3.7	17

#	Article	IF	Citations
221	Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3522-3529.	3.3	9
222	Molecular Imaging of Neurodegenerative Parkinsonism. PET Clinics, 2021, 16, 261-272.	1.5	0
223	A Novel Management Platform Based on Personalized Home Care Pathways for Medicine Management and Rehabilitation of Persons With Parkinson's Diseaseâ€"Requirements and Implementation Plan of the Care-PD Program. Frontiers in Neurology, 2021, 12, 672208.	1.1	3
224	Involvement of the Protein Ras Homolog Enriched in the Striatum, Rhes, in Dopaminergic Neuronsâ€™ Degeneration: Link to Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 5326.	1.8	4
225	Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 9879.	1.6	4
226	Abnormal eye movements in parkinsonism: a historical view. Arquivos De Neuro-Psiquiatria, 2021, 79, 457-459.	0.3	3
227	DJ-1 Protein and Its Role in the Development of Parkinsonâ€™s Disease: Studies on Experimental Models. Biochemistry (Moscow), 2021, 86, 627-640.	0.7	11
228	Therapies for Genetic Forms of Parkinsonâ€™s Disease: Systematic Literature Review. Journal of Neuromuscular Diseases, 2021, 8, 341-356.	1.1	9
229	Pain in Parkinsonâ€™s disease and the role of the subthalamic nucleus. Brain, 2021, 144, 1342-1350.	3.7	21
230	Lactoferrin for Mental Health: Neuro-Redox Regulation and Neuroprotective Effects across the Blood-Brain Barrier with Special Reference to Neuro-COVID-19. Journal of Dietary Supplements, 2023, 20, 218-253.	1.4	5
231	Selective Neuron Vulnerability in Common and Rare Diseasesâ€"Mitochondria in the Focus. Frontiers in Molecular Biosciences, 2021, 8, 676187.	1.6	14
232	Ð'ÐµÐ»Ð¾Ð² DJ-1 Ð¸ ÐµÐ³Ð¾ ÑŒÐ¾Ð»ÑŒ Ð² Ñ€Ð°Ð·Ð²Ð¸Ñ‚Ð¸Ð¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐŸÐ°Ñ€ÐºÐ¸Ð½ÑÐ¾Ð½Ð°. Ð¸Ð·Ð²ÐµÑ	0.0	0
233	Estudo da neuropatia perifÃ©rica em pacientes com doenÃ§a de Parkinson: RevisÃ£o de literatura. Research, Society and Development, 2021, 10, e35410716813.	0.0	0
234	Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6517.	1.8	38
235	Neuroprotective Activities of Crossyne flava Bulbs and Amaryllidaceae Alkaloids: Implications for Parkinsonâ€™s Disease. Molecules, 2021, 26, 3990.	1.7	7
236	Trends and Contributing Factors for Prescribing Antipsychotics in Newly Diagnosed Parkinsonâ€™s Disease Patients: A Population-Based Study. Risk Management and Healthcare Policy, 2021, Volume 14, 2443-2452.	1.2	3
237	Peripheral Immune Profile and Neutrophilâ€toâ€Lymphocyte Ratio in Parkinson's Disease. Movement Disorders, 2021, 36, 2426-2430.	2.2	36
238	Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinsonâ€™s Disease. ENeuro, 2021, 8, ENEURO.0559-20.2021.	0.9	6

#	Article	IF	Citations
239	An Emerging Role for Phosphoinositides in the Pathophysiology of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1725-1750.	1.5	3
240	Ensemble of Deep Transfer Learning Models for Parkinson's Disease Classification. Advances in Intelligent Systems and Computing, 2022, , 135-143.	0.5	8
241	A Î²-Wrapin Targeting the N-Terminus of Î±-Synuclein Monomers Reduces Fibril-Induced Aggregation in Neurons. Frontiers in Neuroscience, 2021, 15, 696440.	1.4	7
242	Parkinsonâ€™s Disease-Related Genes and Lipid Alteration. International Journal of Molecular Sciences, 2021, 22, 7630.	1.8	26
243	Serum lipid profile among sporadic and familial forms of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 59.	2.5	15
244	Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinsonâ€™s disease. PLoS ONE, 2021, 16, e0255274.	1.1	3
245	Attenuated Postprandial GLP-1 Response in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 660942.	1.4	7
246	Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies. Frontiers in Neurology, 2021, 12, 702502.	1.1	6
247	Altered Dynamic Information Flow through the Cortico-Basal Ganglia Pathways Mediates Parkinsonâ€™s Disease Symptoms. Cerebral Cortex, 2021, 31, 5363-5380.	1.6	16
248	Skin erosion in deep brain stimulation procedures: Using the temporalis muscle to treat this complication â€“ A technical note. , 2021, 12, 355.		2
249	Animal Models of Autosomal Recessive Parkinsonism. Biomedicines, 2021, 9, 812.	1.4	6
250	Parkinsonâ€™s Diseaseâ€“An Introduction. Series in Bioengineering, 2022, , 1-24.	0.3	2
251	Neuroprotective effects of coenzyme Q10 in Parkinson's model via a novel Q10/miR-149-5p/MMPs pathway. Metabolic Brain Disease, 2021, 36, 2089-2100.	1.4	10
252	Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 949-970.	1.5	18
253	Distinct globus pallidus circuits regulate motor and cognitive functions. Trends in Neurosciences, 2021, 44, 597-599.	4.2	6
254	A Review on Wearable Technologies for Tremor Suppression. Frontiers in Neurology, 2021, 12, 700600.	1.1	17
255	An End-to-End Deep Learning Approach for Diagnosis of Parkinsonâ€™s Disease Based on Hand Drawing. Journal of Physics: Conference Series, 2021, 1994, 012006.	0.3	0
256	A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons. ELife, 2021, 10, .	2.8	21

#	Article	IF	Citations
257	Insulinâ€degrading enzyme: an ally against metabolic and neurodegenerative diseases. Journal of Pathology, 2021, 255, 346-361.	2.1	29
258	Analysis of Impulse Control Disorders (ICDs) and Factors Associated with Their Development in a Parkinsonâ€™s Disease Population. Healthcare (Switzerland), 2021, 9, 1263.	1.0	1
259	The neuromicrobiology of Parkinsonâ€™s disease: A unifying theory. Ageing Research Reviews, 2021, 70, 101396.	5.0	24
260	Therapeutic Potential of Natural Products in Treating Neurodegenerative Disorders and Their Future Prospects and Challenges. Molecules, 2021, 26, 5327.	1.7	53
261	Gear up for therapeutic application of non-invasive brain stimulation in Parkinsonâ€™s disease. Clinical Neurophysiology, 2021, 132, 2892-2893.	0.7	0
262	Inactivation mode of sodium channels defines the different maximal firing rates of conventional versus atypical midbrain dopamine neurons. PLoS Computational Biology, 2021, 17, e1009371.	1.5	8
263	Inhibition of dynamin-related protein 1 ameliorates the mitochondrial ultrastructure via PINK1 and Parkin in the mice model of Parkinson's disease. European Journal of Pharmacology, 2021, 907, 174262.	1.7	8
264	MACHINE LEARNING ALGORITHMS IMPLEMENTATION IN THE HEALTHCARE SYSTEM AS A PROSPECTIVE AREA FOR SCIENCE, HEALTHCARE, AND BUSINESS. Medical Science of Ukraine (MSU), 2021, 17, 98-109.	0.0	0
266	Genetic analysis of TRIM family genes for early-onset Parkinson's disease in Chinese population. Parkinsonism and Related Disorders, 2021, 90, 105-113.	1.1	2
267	Freezing of saccades in dopa-responsive parkinsonian syndrome. American Journal of Ophthalmology Case Reports, 2021, 23, 101124.	0.4	2
268	The Four Square Step Test for Assessing Cognitively Demanding Dynamic Balance in Parkinsonâ€™s Disease Patients. Journal of Movement Disorders, 2021, 14, 208-213.	0.7	4
269	Impaired age-dependent increases in phosphoglycerate kinase activity in red blood cells of Parkinson's disease patients. Parkinsonism and Related Disorders, 2021, 91, 128-134.	1.1	3
270	Non-motor symptoms in Parkinson's disease: Opening new avenues in treatment. Current Research in Behavioral Sciences, 2021, 2, 100049.	2.4	15
271	Systematic analysis of the molecular mechanisms mediated by coffee in Parkinsonâ€™s disease based on network pharmacology approach. Journal of Functional Foods, 2021, 87, 104764.	1.6	7
272	Dopamine Homeostasis and Role of VMAT2 in Neurodegeneration. , 2021, , 1-22.		0
273	Comprehensive Perspectives on Experimental Models for Parkinsonâ€™s Disease. , 2021, 12, 223.		12
275	Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview. Frontiers in Neuroscience, 2020, 14, 604150.	1.4	31
276	fMRI in Parkinsonâ€™s Disease. , 2020, , 417-431.		1

#	Article	IF	Citations
277	Oxidative stress signaling and regulated cell death in Parkinson's disease. , 2020, , 157-173.		2
278	Decoding Parkinson's disease â€“ iPSC-derived models in the OMICs era. Molecular and Cellular Neurosciences, 2020, 106, 103501.	1.0	4
279	PINK1 and Parkin: The odd couple. Neuroscience Research, 2020, 159, 25-33.	1.0	8
280	Nrf2/Wnt resilience orchestrates rejuvenation of glia-neuron dialogue in Parkinson's disease. Redox Biology, 2020, 36, 101664.	3.9	24
285	Parkinson's disease, aging and adult neurogenesis: Wnt/Î²â€catenin signalling as the key to unlock the mystery of endogenous brain repair. Aging Cell, 2020, 19, e13101.	3.0	105
286	Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. Digital Biomarkers, 2021, 4, 28-49.	2.2	43
287	Parkinson Disease. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 896-918.	0.4	34
288	Secondary Parkinsonism Due to a Large Anterior Cranial Fossa Meningioma. European Journal of Case Reports in Internal Medicine, 2019, 6, 1.	0.2	6
289	The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal. Reviews in the Neurosciences, 2020, 31, 723-742.	1.4	30
290	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 159-167.	1.4	8
291	Metabolic alterations in plasma from patients with familial and idiopathic Parkinsonâ€™s disease. Aging, 2020, 12, 16690-16708.	1.4	32
292	The Pathology of Parkinsonâ€™s Disease and Potential Benefit of Dietary Polyphenols. Molecules, 2020, 25, 4382.	1.7	58
293	An engineered monomer binding-protein for Î±-synuclein efficiently inhibits the proliferation of amyloid fibrils. ELife, 2019, 8, .	2.8	49
294	In vivo functional diversity of midbrain dopamine neurons within identified axonal projections. ELife, 2019, 8, .	2.8	59
295	Predicting Parkinsonâ€™s Disease and Its Pathology via Simple Clinical Variables. Journal of Parkinson's Disease, 2022, 12, 341-351.	1.5	8
296	Glutamatergic Neurons in the Caudal Zona Incerta Regulate Parkinsonian Motor Symptoms in Mice. Neuroscience Bulletin, 2022, 38, 1-15.	1.5	10
298	SINEUPs: a novel toolbox for RNA therapeutics. Essays in Biochemistry, 2021, 65, 775-789.	2.1	13
299	Tremor and Rigidity in Patients with Parkinsonâ€™s Disease: Emphasis on Epidemiology, Pathophysiology and Contributing Factors. CNS and Neurological Disorders - Drug Targets, 2022, 21, 596-609.	0.8	6

#	Article	IF	Citations
300	How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?. Parkinsonism and Related Disorders, 2021, 92, 53-58.	1.1	6
301	Too good to be true. Arquivos De Neuro-Psiquiatria, 2018, 76, 65-66.	0.3	0
305	Nanobiotechnology in Parkinsonâ€™s Disease. , 2019, , 177-208.		0
306	Neurodegenerative Diseases: Parkinson Disease. , 2019, , 1001-1020.		1
307	Neural Synchronization in Parkinsonâ€™s Disease on Different Time Scales. Springer Series in Cognitive and Neural Systems, 2019, , 57-65.	0.1	0
312	The different syndromes in Parkinson's disease: an overview. , 2020, , 235-249.		0
313	Purified anacardic acids exert multiple neuroprotective effects in pesticide model of Parkinson's disease: in vivo and in silico analysis. IUBMB Life, 2020, 72, 1765-1779.	1.5	2
314	ROLE OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN TREATMENT OF COGNITIVE MANIFESTATIONS IN PARKINSON'S DISEASE. Ain Shams Medical Journal, 2020, 71, 281-292.	0.0	0
315	for Orthostatic in Parkinsonâ€™s and Other. Neuromethods, 2021, , 323-365.	0.2	0
316	Microglia-specific overexpression of Î±-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. Nature Communications, 2021, 12, 6237.	5.8	74
317	Basal Ganglia. , 2020, , 591-667.		2
318	Parkinson disease and related disorders. , 2020, , 19-30.		1
319	Stereotyped, automatized and habitual behaviours: are they similar constructs under the control of the same cerebral areas?. AIMS Neuroscience, 2020, 7, 136-152.	1.0	0
320	Deep Brain Stimulation Can Differentiate Subregions of the Human Subthalamic Nucleus Area by EEG Biomarkers. Frontiers in Systems Neuroscience, 2021, 15, 747681.	1.2	4
321	Subjective cognitive decline in idiopathic ParkinsonÂ´s disease: A systematic review. Ageing Research Reviews, 2022, 74, 101508.	5.0	8
323	Epidemiology of Parkinson's disease. Neurologie Pro Praxi, 2020, 21, 390-394.	0.0	1
324	The Role of TMEM230 Gene in Parkinson's Disease. Journal of Parkinson's Disease, 2018, 8, 469-477.	1.5	4
325	Respiratory disorders of Parkinsonâ€™s disease. Journal of Neurophysiology, 2022, 127, 1-15.	0.9	11

#	Article	IF	Citations
326	Autophagy in Î±-Synucleinopathiesâ€"An Overstrained System. Cells, 2021, 10, 3143.	1.8	12
327	The role of frailty in Parkinsonâ€™s disease: a cross-sectional study. Journal of Neurology, 2022, 269, 3006-3014.	1.8	7
328	Quercetin exhibits potent antioxidant activity, restores motor and non-motor deficits induced by rotenone toxicity. PLoS ONE, 2021, 16, e0258928.	1.1	17
329	Common Inflammatory Mechanisms in COVID-19 and Parkinsonâ€™s Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention. Journal of Inflammation Research, 2021, Volume 14, 6349-6381.	1.6	28
330	Reâ€Analysis of the <scp>STEADYâ€PD II</scp> Trialâ€"Evidence for Slowing the Progression of Parkinson's Disease. Movement Disorders, 2022, 37, 334-342.	2.2	20
331	Î±-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox. Cell and Bioscience, 2021, 11, 196.	2.1	8
332	Genetic predisposition to Parkinson's disease and risk of cardio and cerebrovascular disease: a Mendelian randomization study. Parkinsonism and Related Disorders, 2022, 94, 49-53.	1.1	5
333	Can detection and prediction models for Alzheimerâ€™s Disease be applied to Prodromal Parkinsonâ€™s Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.. Open Research Europe, 0, 1, 146.	2.0	0
334	Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain, 2022, 145, 964-978.	3.7	177
335	A review of dementia, focusing on the distinct roles of viral protein corona and MMP9 in dementia: Potential pharmacotherapeutic priorities. Ageing Research Reviews, 2022, 75, 101560.	5.0	13
336	Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2023, 43, 265-281.	1.7	3
337	Cortical excitability changes as a marker of cognitive impairment in Parkinsonâ€™s disease. Behavioural Brain Research, 2022, 422, 113733.	1.2	2
338	Post-Translational Modification of Cav1.2 and its Role in Neurodegenerative Diseases. Frontiers in Pharmacology, 2021, 12, 775087.	1.6	8
339	Parkinsonâ€™s Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering. Diagnostics, 2022, 12, 112.	1.3	12
340	Cannabidiol inhibits methamphetamine-induced dopamine release via modulation of the DRD1-MeCP2-BDNF-TrkB signaling pathway. Psychopharmacology, 2022, , 1.	1.5	3
341	Bioengineered models of Parkinsonâ€™s disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment. Cellular and Molecular Life Sciences, 2022, 79, 78.	2.4	12
342	Prevalence and genotypeâ€“phenotype correlations of GBAâ€related Parkinson disease in a large Chinese cohort. European Journal of Neurology, 2022, 29, 1017-1024.	1.7	12
343	Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases. Frontiers in Neurology, 2021, 12, 792227.	1.1	17

#	Article	IF	Citations
344	Can detection and prediction models for Alzheimerâ€™s Disease be applied to Prodromal Parkinsonâ€™s Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.. Open Research Europe, 0, 1, 146.	2.0	2
345	The Role of the Western Diet and Oral Microbiota in Parkinsonâ€™s Disease. Nutrients, 2022, 14, 355.	1.7	14
346	Current Status of Telemedicine for Parkinsonâ€™s Disease in Japan: A Single-Center Cross-Sectional Questionnaire Survey. Journal of Movement Disorders, 2022, 15, 58-61.	0.7	9
348	Predicting Parkinson's disease using gradient boosting decision tree models with electroencephalography signals. Parkinsonism and Related Disorders, 2022, 95, 77-85.	1.1	25
349	CAV2.3 expression is upregulated in the substantia nigra pars compacta of humans with Parkinson's disease. Brain Disorders, 2022, 5, 100031.	1.1	0
351	The Utility of Breath Analysis in the Diagnosis and Staging of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 993-1002.	1.5	2
352	Efficacy and safety of istradefylline for Parkinsonâ€™s disease: A systematic review and meta-analysis. Neuroscience Letters, 2022, 774, 136515.	1.0	2
353	Dorsal visual stream is preferentially engaged during externally guided action selection in Parkinson Disease. Clinical Neurophysiology, 2021, , .	0.7	2
354	Parkinson's disease: what the model systems have taught us so far. Journal of Genetics, 2018, 97, 729-751.	0.4	4
355	The story of levodopa: A long and arduous journey. Annals of Indian Academy of Neurology, 2022, 25, 124.	0.2	3
356	Gut microbiota and inflammation in Parkinsonâ€™s disease: Pathogenetic and therapeutic insights. European Journal of Inflammation, 2022, 20, 1721727X2210837.	0.2	5
357	Kleine Bewegungen â€“ Tremor. , 2022, , 181-192.		0
358	Therapeutic Devices for Motor Symptoms in Parkinsonâ€™s Disease: Current Progress and a Systematic Review of Recent Randomized Controlled Trials. Frontiers in Aging Neuroscience, 2022, 14, 807909.	1.7	4
359	Neuroprotective effects of ATPase inhibitory factor 1 preventing mitochondrial dysfunction in Parkinson's disease. Scientific Reports, 2022, 12, 3874.	1.6	7
360	Topographic connectivity and cellular profiling reveal detailed input pathways and functionally distinct cell types in the subthalamic nucleus. Cell Reports, 2022, 38, 110439.	2.9	16
361	Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinsonâ€™s Disease: Pathogenesis and Therapeutic Implications. Frontiers in Aging Neuroscience, 2022, 14, 851135.	1.7	7
362	Dietary Inflammatory Index score and prodromal Parkinson's disease incidence: The HELIAD study. Journal of Nutritional Biochemistry, 2022, 105, 108994.	1.9	6
363	Neuropathology of Non-Motor Parkinsonâ€™s Disease Symptoms. , 2022, , 35-45.		0

#	Article	IF	Citations
365	Autoimmune Disease Associated CLEC16A Variants Convey Risk of Parkinsonâ€™s Disease in Han Chinese. Frontiers in Genetics, 2022, 13, 856493.	1.1	6
366	â€œReframingâ€•dopamine signaling at the intersection of glial networks in the aged Parkinsonian brain as innate Nrf2/Wnt driver: Therapeutical implications. Aging Cell, 2022, 21, e13575.	3.0	8
367	Potential Role of Ginger (Zingiber officinale Roscoe) in the Prevention of Neurodegenerative Diseases. Frontiers in Nutrition, 2022, 9, 809621.	1.6	40
368	The Role of Tau beyond Alzheimerâ€™s Disease: A Narrative Review. Biomedicines, 2022, 10, 760.	1.4	12
369	Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo. Biomolecules, 2022, 12, 469.	1.8	9
370	A New Method for the Visualization of Living Dopaminergic Neurons and Prospects for Using It to Develop Targeted Drug Delivery to These Cells. International Journal of Molecular Sciences, 2022, 23, 3678.	1.8	2
371	The Effects of Non-Invasive Brain Stimulation on Quantitative EEG in Patients With Parkinson's Disease: A Systematic Scoping Review. Frontiers in Neurology, 2022, 13, 758452.	1.1	2
372	The pathophysiology of Parkinson's disease tremor. Journal of the Neurological Sciences, 2022, 435, 120196.	0.3	26
373	Striatal dopamine transporter imaging in Parkinsonâ€™s disease drug-naÃ¯ve patients: focus on sexual dysfunction. Neurological Sciences, 2022, 43, 4769-4776.	0.9	6
374	Chapter 5 â€“ â€œParkinson's disease â€“ A role of non-enzymatic posttranslational modifications in disease onset and progression?â€• Molecular Aspects of Medicine, 2022, 86, 101096.	2.7	8
375	Cell models for Alzheimerâ€™s and Parkinsonâ€™s disease: At the interface of biology and drug discovery. Biomedicine and Pharmacotherapy, 2022, 149, 112924.	2.5	18
376	The pathogenesis and treatment mechanism of Parkinson's disease from the perspective of traditional Chinese medicine. Phytomedicine, 2022, 100, 154044.	2.3	14
377	Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes. Neurobiology of Disease, 2022, 167, 105668.	2.1	11
379	Cardiac Changes in Parkinsonâ€™s Disease: Lessons from Clinical and Experimental Evidence. International Journal of Molecular Sciences, 2021, 22, 13488.	1.8	18
380	Neuropathology and molecular diagnosis of Synucleinopathies. Molecular Neurodegeneration, 2021, 16, 83.	4.4	101
381	Does the Montreal Cognitive Assessment (MoCA) identify cognitive impairment profiles in Parkinsonâ€™s disease? An exploratory study. Applied Neuropsychology Adult, 2021, , 1-10.	0.7	0
382	Assessing the Effects of Vitamin D on Neural Network Function in Patients With Parkinsonâ€™s Disease by Measuring the Fraction Amplitude of Low-Frequency Fluctuation. Frontiers in Aging Neuroscience, 2021, 13, 763947.	1.7	5
383	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinsonâ€™s disease. BMC Neurology, 2021, 21, 477.	0.8	7

#	Article	IF	Citations
384	Basal lamina changes in neurodegenerative disorders. Molecular Neurodegeneration, 2021, 16, 81.	4.4	28
385	Parkinsonâ€™s Disease Classification from Magnetic Resonance Images (MRI) using Deep Transfer Learned Convolutional Neural Networks. , 2021, , .		5
387	Does Prefrontal Glutamate Index Cognitive Changes in Parkinsonâ€™s Disease?. Frontiers in Human Neuroscience, 2022, 16, 809905.	1.0	3
427	Alpha-synucleinâ€“mediated DNA damage, STING activation, and neuroinflammation in Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2204058119.	3.3	13
428	Evaluating Oculomotor Tests before and after Vestibular Rehabilitation in Patients with Parkinsonâ€™s Disease: A Pilot Pre-Post Study. Parkinson's Disease, 2022, 2022, 1-6.	0.6	2
430	Validation of a Spatiotemporal Gait Model Using Inertial Measurement Units for Early-Stage Parkinsonâ€™s Disease Detection During Turns. IEEE Transactions on Biomedical Engineering, 2022, 69, 3591-3600.	2.5	8
431	3D Printed Mini-Floating-Polypill for Parkinsonâ€™s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy. Pharmaceutics, 2022, 14, 931.	2.0	18
432	Adaptive changes in striatal projection neurons explain the long duration response and the emergence of dyskinesias in patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2022, 129, 497-503.	1.4	3
433	The Chinese Parkinson's Disease Registry (<scp>CPDR</scp>): Study Design and Baseline Patient Characteristics. Movement Disorders, 2022, 37, 1335-1345.	2.2	13
434	Neurogenesis in aging and age-related neurodegenerative diseases. Ageing Research Reviews, 2022, 78, 101636.	5.0	41
435	Oxidative phosphorylation mediated pathogenesis of Parkinson's disease and its implication via Akt signaling. Neurochemistry International, 2022, 157, 105344.	1.9	6
436	Exercise in Parkinsonâ€™s disease. , 2022, , 403-412.		1
437	A multiple-tissue-specific magnetic resonance imaging model for diagnosing Parkinsonâ€™s disease: a brain radiomics study. Neural Regeneration Research, 2022, 17, 2743.	1.6	5
438	Effects of Ten Different Exercise Interventions on Motor Function in Parkinsonâ€™s Disease Patientsâ€”A Network Meta-Analysis of Randomized Controlled Trials. Brain Sciences, 2022, 12, 698.	1.1	10
439	Novel insights into the role of circular <scp>RNAs</scp> in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases. Journal of Neuroscience Research, 2022, 100, 1775-1790.	1.3	10
440	Lipidomics of Bioactive Lipids in Alzheimerâ€™s and Parkinsonâ€™s Diseases: Where Are We?. International Journal of Molecular Sciences, 2022, 23, 6235.	1.8	19
441	Neuroprotective Mechanisms of Ginsenoside Rb1 in Central Nervous System Diseases. Frontiers in Pharmacology, 0, 13, .	1.6	19
442	The Gut Microbiomeâ€“Brain Crosstalk in Neurodegenerative Diseases. Biomedicines, 2022, 10, 1486.	1.4	20

#	Article	IF	Citations
443	LRRK2 and Proteostasis in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 6808.	1.8	5
445	Extraction of Reduced Infrared Biomarker Signatures for the Stratification of Patients Affected by Parkinsonâ€™s Disease: An Untargeted Metabolomic Approach. Chemosensors, 2022, 10, 229.	1.8	1
446	Therapeutic Potential of Astrocyte Transplantation. Cell Transplantation, 2022, 31, 096368972211054.	1.2	13
447	Transitions and challenges for people with Parkinsonâ€™s and their family members: A qualitative study. PLoS ONE, 2022, 17, e0268588.	1.1	4
448	The Emerging Applications of Nanotechnology in Neuroimaging: A Comprehensive Review. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	2
449	A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinsonâ€™s disease with dementia. Brain Communications, 2022, 4, .	1.5	3
450	Insights Into the Role of Mortalin in Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and HIV-1-Associated Neurocognitive Disorders. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	6
451	New Targets and New Technologies in the Treatment of Parkinsonâ€™s Disease: A Narrative Review. International Journal of Environmental Research and Public Health, 2022, 19, 8799.	1.2	10
452	Age Cutoff for Earlyâ€Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease. Movement Disorders Clinical Practice, 2022, 9, 869-878.	0.8	26
453	Alpha-Synuclein Clearance through Inhibiting Akt/mTOR Pathway by Microfluidic Encapsulated Induced Conjunctival MSCs in a Parkinsonian Model. Iranian Journal of Pathology, 2022, 17, 342-353.	0.2	0
454	Targeting Mitochondria as a Therapeutic Approach for Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2023, 43, 1499-1518.	1.7	7
455	Metabolic Profile Variations along the Differentiation of Human-Induced Pluripotent Stem Cells to Dopaminergic Neurons. Biomedicines, 2022, 10, 2069.	1.4	1
457	Moving goals. Goal-work in Parkinson's disease rehabilitation. Frontiers in Rehabilitation Sciences, 0, 3, .	0.5	1
458	Who to Enroll in Parkinson Disease Prevention Trials?. Neurology, 2022, 99, 26-33.	1.5	6
459	Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinsonâ€™s disease. Frontiers in Pharmacology, 0, 13, .	1.6	8
460	Rabphilin-3A as a novel target to reverse Î±-synuclein-induced synaptic loss in Parkinsonâ€™s disease. Pharmacological Research, 2022, 183, 106375.	3.1	13
461	The many genomes of Parkinson's disease. International Review of Neurobiology, 2022, , .	0.9	2
462	Striatal Neurons Partially Expressing a Dopaminergic Phenotype: Functional Significance and Regulation. International Journal of Molecular Sciences, 2022, 23, 11054.	1.8	3

#	Article	IF	Citations
463	L-Ornithine L-Aspartate Restores Mitochondrial Function and Modulates Intracellular Calcium Homeostasis in Parkinsonâ€™s Disease Models. Cells, 2022, 11, 2909.	1.8	6
464	Current Insights on Neurodegeneration by the Italian Proteomics Community. Biomedicines, 2022, 10, 2297.	1.4	3
465	Mild cognitive impairment in patients with Parkinsonâ€™s disease: An updated mini-review and future outlook. Frontiers in Aging Neuroscience, 0, 14, .	1.7	7
466	Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: A systematic review. Frontiers in Neurology, 0, 13, .	1.1	6
467	Environmental exposure to metals and the development of tauopathies, synucleinopathies, and TDP-43 proteinopathies: A systematic evidence map protocol. Environment International, 2022, 169, 107528.	4.8	4
468	Extension of community healthcare outcomes in Parkinson disease (Parkinson ECHO): A feasibility study. Clinical Parkinsonism & Related Disorders, 2022, 7, 100167.	0.5	0
469	Measuring the Usability of eHealth Solutions for Patients With Parkinson Disease: Observational Study. JMIR Formative Research, 2022, 6, e39954.	0.7	4
470	Nanomedicine in the Face of Parkinsonâ€™s Disease: From Drug Delivery Systems to Nanozymes. Cells, 2022, 11, 3445.	1.8	7
471	Molecular imaging in prodromal Parkinsonâ€™s disease. , 2023, , 251-272.		0
472	Metagenomics of Parkinsonâ€™s disease implicates the gut microbiome in multiple disease mechanisms. Nature Communications, 2022, 13, .	5.8	73
473	Inflammatory rheumatic diseases and the risk of Parkinson's disease: A systematic review and meta-analysis. Frontiers in Neurology, 0, 13, .	1.1	2
474	Development of the Forman Parkinsonâ€™s Disease Symptom Checklist. Journal of Professional & Applied Psychology, 2022, 3, 356-370.	0.1	0
476	Neuroinflammation and Autophagy in Parkinsonâ€™s Diseaseâ€”Novel Perspectives. International Journal of Molecular Sciences, 2022, 23, 14997.	1.8	11
477	Approaching the Gut and Nasal Microbiota in Parkinsonâ€™s Disease in the Era of the Seed Amplification Assays. Brain Sciences, 2022, 12, 1579.	1.1	3
479	Genetic analysis of the LRP10 gene in Chinese patients with Parkinsonâ€™s disease. Neurological Sciences, 2023, 44, 905-912.	0.9	5
480	A Focus on Astrocyte Contribution to Parkinsonâ€™s Disease Etiology. Biomolecules, 2022, 12, 1745.	1.8	3
481	A Newly Identified Monoterpenoid-Based Small Molecule Able to Support the Survival of Primary Cultured Dopamine Neurons and Alleviate MPTP-Induced Toxicity In Vivo. Molecules, 2022, 27, 8286.	1.7	4
482	An intensive neurorehabilitation programme with sEMG biofeedback to improve swallowing in idiopathic Parkinson's disease (IPD): A feasibility study. International Journal of Language and Communication Disorders, 2023, 58, 813-825.	0.7	3

#	Article	IF	Citations
483	Manual and semi-automated approaches to MIBG myocardial scintigraphy in patients with Parkinsonâ€™s disease. Frontiers in Medicine, 0, 9, .	1.2	2
484	Characterisation of functional deficits induced by AAV overexpression of alpha-synuclein in rats. Current Research in Neurobiology, 2023, 4, 100065.	1.1	2
485	Modeling Pacemaking, Bursting, and Depolarization Block in Midbrain Dopamine Neurons. Neuromethods, 2023, , 101-119.	0.2	1
486	Zinc Deficiency Exacerbates Behavioral Impediments and Dopaminergic Neuron Degeneration in a Mouse Model of Parkinson Disease. Journal of Nutrition, 2023, 153, 167-175.	1.3	1
487	Rotenone-Induced Model of Parkinsonâ€™s Disease: Beyond Mitochondrial Complex I Inhibition. Molecular Neurobiology, 2023, 60, 1929-1948.	1.9	16
488	Dopamine Homeostasis and Role of VMAT2 in Neurodegeneration. , 2022, , 291-311.		0
489	Brain-enriched miR-128: Reduced in exosomes from Parkinsonâ€™s patient plasma, improves synaptic integrity, and prevents 6-OHDA mediated neuronal apoptosis. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	10
490	Mendelian Randomization Analysis Reveals No Causal Relationship Between Plasma Î±-Synuclein and Parkinsonâ€™s Disease. Molecular Neurobiology, 0, , .	1.9	0
491	Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand?. Movement Disorders, 2023, 38, 558-566.	2.2	15
492	Effects of non-invasive brain stimulation on walking and balance ability in Parkinsonâ€™s patients: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
493	Distribution of Cleaved SNAP-25 in the Rat Brain, following Unilateral Injection of Botulinum Neurotoxin-A into the Striatum. International Journal of Molecular Sciences, 2023, 24, 1685.	1.8	0
494	Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia. Neuropharmacology, 2023, 226, 109411.	2.0	6
495	Cognitive and Functional Trajectories in Older Adults With Prediagnostic Parkinson Disease. Neurology, 2023, 100, .	1.5	4
496	Deep Brain Stimulation for Advanced Parkinson Disease in Developing Countries: A Cost-Effectiveness Study From China. Neurosurgery, 2023, 92, 812-819.	0.6	2
497	Dendrimers in Neurodegenerative Diseases. Processes, 2023, 11, 319.	1.3	7
498	Peripheral inflammatory immune response differs among sporadic and familial Parkinsonâ€™s disease. Npj Parkinson's Disease, 2023, 9, .	2.5	10
499	Environmental and genetic risk factors for Parkinsonâ€™s disease. Bulletin of Siberian Medicine, 2023, 21, 105-113.	0.1	0
500	How Organ-on-a-Chip Technology Can Assist in Studying the Role of the Glymphatic System in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2023, 24, 2171.	1.8	5

#	Article	IF	Citations
501	Disease mechanisms as subtypes: Microbiome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 107-131.	1.0	2
502	Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 15, .	1.7	4
503	Suppression of neuroinflammation and Î±-synuclein oligomerization by rotarod walking exercise in subacute MPTP model of Parkinson's disease. Neurochemistry International, 2023, 165, 105519.	1.9	4
504	Cell type- and region-specific translatomes in an MPTP mouse model of Parkinson's disease. Neurobiology of Disease, 2023, 180, 106105.	2.1	2
505	African walnut (Tetracarpidium conophorum) extract upregulates glucocerebrosidase activity and circumvents Parkinsonian changes in the Hippocampus via the activation of heatshock proteins. Journal of Chemical Neuroanatomy, 2023, 130, 102271.	1.0	1
506	Protective Effects of Flavonoid Rutin Against Aminochrome Neurotoxicity. Neurotoxicity Research, 0, , .	1.3	3
507	The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 3-20.	1.0	1
508	Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 67-93.	1.0	0
509	Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 95-106.	1.0	4
510	Introduction to Diagnostic Challenges in Movement Disorders. Seminars in Neurology, 2023, 43, 002-003.	0.5	0
511	Mechanisms of Glucocerebrosidase Dysfunction in Parkinsonâ€™s Disease. Journal of Molecular Biology, 2023, 435, 168023.	2.0	7
513	Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease. Movement Disorders, 2023, 38, 755-763.	2.2	5
514	Diagnostic Uncertainties in Tremor. Seminars in Neurology, 2023, 43, 156-165.	0.5	2
515	Protection and Repair of the Nigrostriatal Pathway with Stem-Cell-Derived Carotid Body Glomus Cell Transplants in Chronic MPTP Parkinsonian Model. International Journal of Molecular Sciences, 2023, 24, 5575.	1.8	2
516	Mobile Applications for Resting Tremor Assessment in Parkinsonâ€™s Disease: A Systematic Review. Journal of Clinical Medicine, 2023, 12, 2334.	1.0	1
517	Neurocognitive Psychiatric and Neuropsychological Alterations in Parkinsonâ€™s Disease: A Basic and Clinical Approach. Brain Sciences, 2023, 13, 508.	1.1	6
518	Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface. Advances in Experimental Medicine and Biology, 2023, , 435-458.	0.8	2
519	Extracellular matrix protein anosmin-1 overexpression alters dopaminergic phenotype in the CNS and the PNS with no pathogenic consequences in a MPTP model of Parkinsonâ€™s disease. Brain Structure and Function, 0, , .	1.2	0

#	Article	IF	Citations
520	Migratory Response of Cells in Neurogenic Niches to Neuronal Death: The Onset of Harmonic Repair?. International Journal of Molecular Sciences, 2023, 24, 6587.	1.8	3
521	Introduction to Diagnostic Challenges in Movement Disorders. Seminars in Neurology, 2023, 43, 002-003.	0.5	0
522	Rigidity in Parkinsonâ€™s disease: Evidence from biomechanical and neurophysiological measures. Brain, 0, , .	3.7	1
523	Dynamic Involvement of Striatal NG2-glia in L-DOPA Induced Dyskinesia in Parkinsonian Rats: Effects of Doxycycline. ASN Neuro, 2023, 15, 175909142311559.	1.5	2
524	Imaging the lower limb network in Parkinsonâ€™s disease. NeuroImage: Clinical, 2023, 38, 103399.	1.4	1
525	The return of the lesion for localization and therapy. Brain, 2023, 146, 3146-3155.	3.7	3
526	An upconversion nanoplatform based multi-effective theatment for Parkinsonâ€™s disease. Chemical Engineering Journal, 2023, 465, 142959.	6.6	1
527	Identification of Hub Genes and Potential Molecular Pathogenesis in Substantia Nigra in Parkinsonâ€™s Disease via Bioinformatics Analysis. Parkinson's Disease, 2023, 2023, 1-17.	0.6	0
529	Proteins and Transcriptional Dysregulation of the Brain Extracellular Matrix in Parkinsonâ€™s Disease: A Systematic Review. International Journal of Molecular Sciences, 2023, 24, 7435.	1.8	6
530	Serum levels of p-tau181 in patients with Parkinsonâ€™s disease. , 2023, 2, 19-23.		0
531	Neuroprotective Effects of Ecklonia cava in a Chronic Neuroinflammatory Disease Model. Nutrients, 2023, 15, 2007.	1.7	4
532	Chronic H3R activation reduces L-Dopa-induced dyskinesia, normalizes cortical GABA and glutamate levels, and increases striatal dopamine D1R mRNA expression in 6-hydroxydopamine-lesioned maleÂrats. Psychopharmacology, 0, , .	1.5	0
542	The heterogeneity of Parkinsonâ€™s disease. Journal of Neural Transmission, 2023, 130, 827-838.	1.4	10
595	Neuroprotection induced by apigenin. , 2024, , 1241-1262.		0
596	Classification of Alzheimer??s Disease using combined features of fMRI Brain Network and clinical scales. , 2023, , .		0
597	Neuroprotection induced by coumarins in central nervous system disease models. , 2024, , 1411-1440.		0
598	Gut Microbes in Parkinson's Disease. , 2024, , 217-240.		0